{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:36:59Z","timestamp":1763429819540,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharmaceutical"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p &lt; 0.001), smoking (HR = 5.08, p &lt; 0.001), dyslipidemia (HR = 4.65, p &lt; 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p &lt; 0.001), pulmonary disease (HR = 3.13, p &lt; 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p &lt; 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.<\/jats:p>","DOI":"10.3390\/cancers14092331","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T21:23:27Z","timestamp":1652131407000},"page":"2331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis"],"prefix":"10.3390","volume":"14","author":[{"given":"Mar\u00eda","family":"Garc\u00eda-Fortes","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario Virgen de la Victoria, 29010 M\u00e1laga, Spain"},{"name":"Facultad de Medicina, Universidad de M\u00e1laga, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan C.","family":"Hern\u00e1ndez-Boluda","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednico, INCLIVA, 46010 Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Raya","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Canarias, 38320 Santa Cruz de Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital del Mar, 08003 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Estrada","sequence":"additional","affiliation":[{"name":"Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0062-6607","authenticated-orcid":false,"given":"Laura","family":"Fox","sequence":"additional","affiliation":[{"name":"Hematology Department, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Hospital Universitari, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7555-3361","authenticated-orcid":false,"given":"Beatriz","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda C.","family":"Garc\u00eda-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital General Universitario de Alicante, 03010 Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Teresa","family":"G\u00f3mez-Casares","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Doctor Negr\u00edn, 35010 Las Palmas de Gran Canaria, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9520-3243","authenticated-orcid":false,"given":"Francisca","family":"Ferrer-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital General Universitario Morales Meseguer, CIBERER, IMIB, UCAM, 30008 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana","family":"Saavedra","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Santa Creu i Sant Pau, 08025 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Garc\u00eda-Delgado","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Virgen de la Victoria, 29010 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Grupo Espa\u00f1ol de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed Criteria for the Diagnosis of Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Consensus Statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast Transformation and Fibrotic Progression in Polycythemia Vera and Essential Thrombocythemia: A Literature Review of Incidence and Risk Factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_4","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2016). WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, IARC. [4th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of Myelofibrosis, Essential Thrombocythemia, and Polycythemia Vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and Patient Survival of Myeloproliferative Neoplasms and Myelodysplastic\/Myeloproliferative Neoplasms in the United States, 2001\u20132012","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-Mutated or Triple-Negative Myelofibrosis: Clinical, Cytogenetic and Molecular Comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and Prognosis in Primary Myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2004.00.9316","article-title":"Pathogenesis of Myelofibrosis with Myeloid Metaplasia","volume":"23","author":"Tefferi","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary Myelofibrosis: 2017 Update on Diagnosis, Risk-Stratification, and Management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2017.1.489","article-title":"Current Treatment Algorithm for the Management of Patients with Myelofibrosis, JAK Inhibitors, and Beyond","volume":"2017","author":"Harrison","year":"2017","journal-title":"Hematology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and Management of Allogeneic Stem Cell Transplantation in Primary Myelofibrosis: A Consensus Process by an EBMT\/ELN International Working Group","volume":"29","author":"Deeg","year":"2015","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of Allogeneic Stem Cell Transplantation on Survival of Patients Less than 65 Years of Age with Primary Myelofibrosis","volume":"125","author":"Giorgino","year":"2015","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: A Study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project","volume":"124","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically Inspired Prognostic Scoring System for Primary Myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/leu.2017.297","article-title":"Performance of the Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) in a Series of 262 Patients from the Spanish Registry of Myelofibrosis","volume":"32","author":"Pereira","year":"2018","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in Myeloproliferative Neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, Risk Stratification, and Response Evaluation in Classical Myeloproliferative Neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of Comorbidities on Overall Survival in Patients with Chronic Myeloid Leukemia: Results of the Randomized CML Study IV","volume":"126","author":"Hehlmann","year":"2015","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities Predict Inferior Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of Comorbidities with Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s13670-017-0227-8","article-title":"Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia","volume":"6","author":"Storey","year":"2017","journal-title":"Curr. Geriatr. Reports"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.13000","article-title":"Impact of Comorbidities Constituting the Hematopoietic Cell Transplant (HCT)-Comorbidity Index on the Outcome of Patients Undergoing Allogeneic HCT for Acute Myeloid Leukemia","volume":"100","author":"Khalil","year":"2018","journal-title":"Eur. J. Haematol"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3322\/caac.21342","article-title":"The Impact of Comorbidity on Cancer and Its Treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J. Clin"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jgo.2012.01.006","article-title":"Comparison of Scoring Methods for ACE-27: Simpler Is Better","volume":"3","author":"Kallogjeri","year":"2012","journal-title":"J. Geriatr. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.clml.2017.06.031","article-title":"Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study","volume":"17","author":"Bartoszko","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/cncr.28857","article-title":"Comorbidities Predict Worse Prognosis in Patients with Primary Myelofibrosis","volume":"120","author":"Newberry","year":"2014","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0869-8","article-title":"Contribution of Comorbidities and Grade of Bone Marrow Fibrosis to the Prognosis of Survival in Patients with Primary Myelofibrosis","volume":"31","author":"Lekovic","year":"2014","journal-title":"Med. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System among Patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2009.02.007","article-title":"Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Single and Multiple Institutions: Limitations and Inferences","volume":"15","author":"Sorror","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-018-3569-1","article-title":"Impact of Comorbidities and Body Mass Index in Patients with Myelofibrosis Treated with Ruxolitinib","volume":"98","author":"Breccia","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"104060","DOI":"10.1016\/j.mvr.2020.104060","article-title":"Ruxolitinib Attenuates Intimal Hyperplasia via Inhibiting JAK2\/STAT3 Signaling Pathway Activation Induced by PDGF-BB in Vascular Smooth Muscle Cells","volume":"132","author":"Song","year":"2020","journal-title":"Microvasc. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1586\/17474086.2013.876356","article-title":"Perspectives on the Impact of JAK-Inhibitor Therapy upon Inflammation-Mediated Comorbidities in Myelofibrosis and Related Neoplasms","volume":"7","author":"Hasselbalch","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ccr3.281","article-title":"The Impact of Ruxolitinib Treatment on Inflammation-Mediated Comorbidities in Myelofibrosis and Related Neoplasms","volume":"3","author":"Hasselbalch","year":"2015","journal-title":"Clin. Case Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lee, J.H., Kim, S.H., Kang, S.H., Cho, J.H., Cho, Y., Oh, I.Y., Yoon, C.H., Lee, H.Y., Youn, T.J., and Chae, I.H. (2018). Blood Pressure Control and Cardiovascular Outcomes: Real-World Implications of the 2017 ACC\/AHA Hypertension Guideline. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-31549-5"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The Legacy Effect in Type 2 Diabetes:Impactofearlyglycemic Control on Future Complications (the Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.kint.2017.09.011","article-title":"Lowering LDL Cholesterol Reduces Cardiovascular Risk Independently of Presence of Inflammation","volume":"93","author":"Storey","year":"2018","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1871529X17666171030122345","article-title":"Cardiovascular Events: A Challenge in JAK2-Positive Myeloproliferative Neoplasms","volume":"17","author":"Haybar","year":"2018","journal-title":"Cardiovasc. Hematol. Disord. Targets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2147\/CLEP.S216787","article-title":"Vascular Diseases in Patients with Chronic Myeloproliferative Neoplasms\u2014Impact of Comorbidity","volume":"11","author":"Frederiksen","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Golia, E., Limongelli, G., Natale, F., Fimiani, F., Maddaloni, V., Pariggiano, I., Bianchi, R., Crisci, M., D\u2019Acierno, L., and Giordano, R. (2014). Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. Curr. Atheroscler. Rep., 16.","DOI":"10.1007\/s11883-014-0435-z"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:08:00Z","timestamp":1760137680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092331"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092331","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,5,9]]}}}